Biotech

All Articles

Kairos goes public with $6M IPO to fund trials of cancer medicine

.Along with a trio of biotechs hitting the Nasdaq on Friday, it was easy to skip a smaller-scale pub...

Vaccine and Keytruda combo helpful in squamous cell carcinoma

.Immune system checkpoint inhibitors are actually the superheroes of cancer therapy. Medicines like ...

Cue Biopharma mark time J&ampJ veterinarian as CBO-- Chutes &amp Ladders

.Welcome to this week's Chutes &amp Ladders, our summary of significant management hirings, shooting...

Regeneron's Opdualag competitor presents 57% feedback rate

.Regeneron is back with lasting consequence for its own LAG-3 prevention and PD-1 prevention combo i...

AstraZeneca messages data on in-house opponents to AbbVie, Pfizer ADCs

.AstraZeneca has shared an early examine the functionality of its own internal antibody-drug conjuga...

iTeos- GSK's TIGIT superstar shows purposeful enhancement

.After declaring a phase 3 launch based on good midstage end results, iTeos as well as GSK are ultim...

More joint FDA may speed up unusual disease R&ampD: record

.The FDA needs to be actually much more available and joint to let loose a surge in approvals of rar...

Zenas, MBX, Bicara head to Nasdaq in warm day for biotech IPOs

.It's an extraordinarily hectic Friday for biotech IPOs, along with Zenas BioPharma, MBX and also Bi...

Atea's COVID antiviral stops working to stop hospitalizations in period 3

.Atea Pharmaceuticals' antiviral has failed an additional COVID-19 trial, yet the biotech still stor...

Neurocrine's offer to spare schizophrenia possibility stops working

.Neurocrine Biosciences' schizophrenia course pivot has failed. The biotech was actually not able to...